Acertil

Servier is a global independent pharmaceutical group governed by a non-profit foundation, with a strong focus on cardiovascular and metabolic diseases, oncology, neuroscience, and immuno-inflammation. The company is the original developer and manufacturer of Acertil (perindopril), a leading ACE inhibitor used widely for the treatment of hypertension and heart failure. Servier has significantly expanded its oncology portfolio in recent years through strategic acquisitions, including the oncology business of Shire and Agios Pharmaceuticals. The group operates a robust international commercial infrastructure and invests a substantial portion of its revenue into research and development to address high unmet medical needs.